Abstract:Alzheimer's disease is a progressive neurodegenerative disorder characterised by the gradual onset of dementia. The pathological hallmarks of the disease are beta-amyloid (Abeta) plaques, neurofibrillary tangles, synaptic loss and reactive gliosis. The current therapeutic effort is directed towards developing drugs that reduce Abeta burden or toxicity by inhibiting secretase cleavage, Abeta aggregation, Abeta toxicity, Abeta metal interactions or by promoting Abeta clearance. A number of clinical trials are currently in progress based on these different therapeutic strategies and they should indicate which, if any, of these approaches will be efficacious. Current diagnosis of Alzheimer's disease is made by clinical, neuropsychologic and neuroimaging assessments. Routine structural neuroimaging evaluation with computed tomography and magnetic resonance imaging is based on non-specific features such as atrophy, a late feature in the progression of the disease, hence the crucial importance of developing new approaches for early and specific recognition at the prodromal stages of Alzheimer's disease. Functional neuroimaging techniques such as functional magnetic resonance imaging, magnetic resonance spectroscopy, positron emission tomography and single photon emission computed tomography, possibly in conjunction with other related Abeta biomarkers in plasma and CSF, could prove to be valuable in the differential diagnosis of Alzheimer's disease, as well as in assessing prognosis. With the advent of new therapeutic strategies there is increasing interest in the development of magnetic resonance imaging contrast agents and positron emission tomography and single photon emission computed tomography radioligands that will permit the assessment of Abeta burden in vivo.

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease

Multimodal Identification of Alzheimer's Disease: A Review

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future

Early-Stage Identification and Pathological Development of Alzheimer's Disease Using Multimodal MRI.

Detection and treatment of Alzheimer’s disease in its preclinical stage

Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer's Disease

Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies

Molecular imaging in early diagnosis, differential diagnosis and follow-up of patients with neurodegenerative diseases

Multimodal 3D Deep Learning for Early Diagnosis of Alzheimer's Disease

Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images

Early Detection of Alzheimer’s disease by using the Latest Techniques

Research progress in multimodal imaging analysis of Alzheimer's disease

Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer’s Disease

IMAGING MICROSCOPIC NEUROPATHOLOGY OF ALZHEIMER’S DISEASE USING MRI: FROM MODEL SYSTEMS TO HUMAN IN VIVO

An Algorithm for Preclinical Diagnosis of Alzheimer's Disease

Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)

Toward a multimodal multitask model for neurodegenerative diseases diagnosis and progression prediction

A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages

Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms